The chemokine, CXCL12, promotes cancer growth and metastasis through interaction with either CXCR4 and/or CXCR7. This tumor-specific organization of the CXCL12 system obscures current therapeutic approaches, aiming at the selective inactivation of CXCL12 receptors. Since it has been previously suggested that the cellular use of CXCR4 or CXCR7 is dictated by the 5T4 oncofetal glycoprotein, we have now tested whether 5T4 would represent a general and reliable marker for the organization of the CXCL12 system in cancer cells. The CXCR4 antagonist, AMD3100, as well as the CXCR7 antagonist, CCX771, demonstrated that the cancer cell lines A549, C33A, DLD-1, MDA-231, and PC-3 use either CXCR7 and/or CXCR4 for mediating CXCL12-induced chemotaxis and cell proliferation. The use of CXCL12 receptors as well as their subcellular localization remained unchanged in most cell lines following siRNA-mediated depletion of 5T4. In distinct cell lines, inhibition of 5T4 expression, however, modulated tumor cell migration and proliferation per se. Collectively our analyses fail to demonstrate general organizational influences of 5T4 of the CXCL12 system in different cancer cell lines, and, hence, dismiss its future use as a diagnostic marker.
Introduction
The chemokine, CXCL12, promotes growth and metastasis of tumors from different organs, such as breast, prostate, ovary, lung, gastrointestinal tract, brain, blood, and kidney [1, 2] . Depending on the type of tumor and/or patient these effects are either mediated by CXCR4 and/or CXCR7/atypical chemokine receptor 3 (ACKR3) [2] . Consequently, delineation of the heterogeneous organization of the CXCL12 system in individual tumors may play a key role in guidance of future therapeutic strategies using CXCL12 receptor antagonists/inhibitors.
The 5T4 oncofetal glycoprotein (trophoblast glycoprotein, TPBG) is a highly glycosylated transmembrane protein which belongs to the leucine-rich repeat (LRR) protein family and affects cell adhesion, mobility, and cytoskeletal organization [3] . 5T4 is sparsely expressed in normal adult tissue, but present in most tumors [3, 4] . By using murine embryonic fibroblasts and small cell lung carcinoma cell lines a previous study suggested that cell surface expression of 5T4 would mark the use of CXCR4, whereas CXCL12 signaling would occur through CXCR7 in its absence [5] .
We now asked whether 5T4 represents a general and reliable marker for the organization of the CXCL12 system in tumor cells. To this end, we defined the involvement of CXCR4 and/or CXCR7 in CXCL12 signaling in various cancer cell lines and determined how this relates to cellular 5T4 expression. In addition, we investigated how inhibition of 5T4 expression would affect the use of CXCL12 receptors in these cells.
Materials and methods

Cell cultures
The human lung adenocarcinoma cell line, A549, the human cervical cancer cell line, C33A, the human colorectal adenocarcinoma cell line, DLD-1, the human breast adenocarcinoma cell line, MDA-MB-231 (MDA-231), the human neuroglioma cell line, H4, and the human prostate adenocarcinoma cell line, PC-3, were obtained from ATCC and maintained in either Dulbecco's modified eagle medium (DMEM) (4.5 g/l glucose; LONZA; Verviers, Belgium; C33A, MDA-231, H4, PC-3) or RPMI 1640 (Life Technologies; Carlsbad, CA; A549, DLD-1). Media were supplemented with 0.05% Gentamycin (Life Technologies) and 10% fetal bovine serum (Life Technologies). Cells were plated on 10 cm culture dishes (TPP, Sigma, Munich, Germany), subconfluent cultures were used for experiments. In selected experiments, cells were seeded on culture plates previously coated with poly-L-ornithine (Sigma).
Immunological methods
Western blot (WB) analysis and immunofluorescence (IF) staining of cultured cells were performed as previously described [6, 7] using the following primary antibodies: goat anti-CXCR4 (ab1670, Abcam, WB, 1:1000; IF, 1:100); rabbit anti-CXCR7 (AP17961PU-N, Acris, WB, 1:300; IF, 1:100; ab138509, Abcam, WB, 1:1000); rabbit anti-5T4 (ab129058, Abcam, WB, 1:1000). Protein loading was controlled by additionally staining blots with anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies (10R-G109A, Fitzgerald, 1:5000). Cell nuclei in immunostained cell cultures were visualized with 4′,6-diamidino-2-phenylindole (DAPI; AAT Bioquest, Sunnyvale, CA) and inspected on a Zeiss confocal laser scan microscope (LSM).
RNA interference
Predesigned human 5T4 (SI03194478, SI104192811) and negative control (SI03194478) siRNAs were purchased from Qiagen (Hilden, Germany). Transfection was performed in the presence of serum-free medium using either the siPORT™ Amine Transfection Agent (Ambion, Huntingdon, UK) or the Viromer Blue Transfection Agent (Lipocalyx, Halle, Germany). Cells were taken into experiment 24-48 h after transfection. Success of RNA interference was validated by Western blotting.
Chemotaxis
The chemotactic response of cancer cells to CXCL12 (Almac, East Lothian, Scotland) was evaluated using a modified 48-well Boyden chamber (Neuro Probe, Cabin John, MD), as previously described [7] . One hour prior to analysis, cultured cells were treated with one of the following substances: AMD3100, a selective antagonist for CXCR4 (10 µM; Sigma, dissolved in double-distilled water), CCX771, a selective antagonist for CXCR7 (100 nM; ChemoCentryx; Mountain View, CA), dissolved in dimethyl sulfoxide (DMSO) or CCX704, a compound chemically similar to CCX771, which however does not bind CXCR7 (100 nM; ChemoCentryx; dissolved in DMSO). Migration index was defined as the ratio of cells migrating in the presence and absence of chemokines.
MTT assay
Cells were seeded into 96-well plates at a density of 5000 cells/well, cultivated overnight at 37°C, and transfected with siRNA. 24 h after transfection cells were treated with CXCL12 (100 ng/ml); AMD3100 (10 µM), CCX771 (100 nM) or CCX704 (100 nM) for 48 h alone or in combination as specified. Treatment was repeated daily. Cell numbers were assessed using the Vybrant® MTT Cell Proliferation Assay Kit according to the manufacturer's recommendations. Cell proliferation occurring in untreated controls was set to 1.
Statistics
Data, obtained from at least three experiments, are given as mean ± SD. One way analysis of variance (ANOVA) followed by pairwise multiple comparison procedures (Tukey post-hoc test) or twotailed Student's t-test was used for statistical analysis as appropriate. Differences with p < 0.05 were considered significant.
Results
Analysis of cancer cell lines for expression of 5T4 and CXCL12 receptors
In the cancer cell lines, A549, C33A, DLD-1, MDA-231, and PC-3, 5T4 expression was readily detectable by Western blot analysis with highest expression levels in MDA-231 and PC-3 cells (Fig. 1) . The only exception was the cell line, H4, which completely lacked 5T4 and was subsequently omitted from all further experiments. Notably, the 5T4 antibody detected two immunoreactive protein bands (approximately 72 kDa and 55 kDa), which both decreased following transfection of the cells with selective 5T4 siRNAs (see Fig. 6 , Suppl. Fig. 1 ). In addition to 5T4, all cancer cell lines expressed CXCR4 and CXCR7 to detectable levels ( Fig. 1). 
Heterogeneous organization of the CXCL12 system in tumor cell lines
Since previous studies suggested that CXCL12 signals either through CXCR4 and/or CXCR7 in different tumor cells [2] and/or differentially controls cell functions through these receptors [1, [8] [9] [10] , we analyzed the contribution of CXCR4 and CXCR7 to CXCL12-dependent chemotaxis and cell proliferation of the various tumor cell lines. To this end, we determined the respective cellular responses to CXCL12 in the presence of either the specific CXCR4 antagonist, AMD3100, the specific CXCR7 antagonist, CCX771, or the CCX771 control peptide, CCX704. We routinely used CXCL12 at 100 ng/ml, a concentration previously shown to induce maximal cellular responses [6, 11] . All tumor cell lines potently migrated towards CXCL12 in a modified Boyden chamber, as evidenced by a 2-to 4-fold increase of their migration index (Fig. 2) . The CXCL12-dependent chemotactic responses of C33A, MDA-231, and PC-3 cells were likewise attenuated by AMD3100 and CCX771, but not by CCX704 (Fig. 2) . The chemotactic responses of A594 and DLD-1 cells to CXCL12 were only attenuated by CCX771, whereas AMD3100 had no statistically significant effects (Fig. 2) . In DLD-1 cells, CCX704 also reduced CXCL12-dependent chemotaxis although to a much smaller extent than CCX771 (Fig. 2 ). This effect is most likely due to DMSO, which served as a solvent. Indeed, a similar decline of CXCL12-induced chemotaxis occurred when DLD-1 cells were treated with DMSO alone (data not shown).
MTT assay demonstrated increased numbers of C33A, MDA-231, and PC-3 cells following treatment with CXCL12 (100 ng/ml) for 48 h (Fig. 3 ). Higher concentrations of the chemokine (≥ 300 ng/ml) produced either smaller or no increases in cell numbers (Fig. 3) . Irrespective of the concentration, CXCL12 failed to affect numbers of A549 and DLD-1 cells (Fig. 3) . The same applied when these cells were assayed on coated culture plates (data not shown). We consequently suggest that the absence of CXCL12-dependent increases in A549 and DLD-1 cell numbers is rather due to already maximal cell proliferation under control conditions than to the CXCL12-induced loss or decline of cell adhesion and the subsequent detachment of cells from the culture plate. Comparable to our findings from chemotaxis, CXCL12-induced increases in C33A cell numbers were sensitive to both AMD3100 and CXC771 (Fig. 4) . However, discrepant from chemotaxis, only AMD3100, but not CCX771, attenuated CXCL12-induced increases in MDA-231 and PC-3 cell numbers (Fig. 4) . Collectively, these findings establish that the organization of the CXCL12 system differs within the tumor cell lines examined, and further reveal that within distinct tumor cell lines, different CXCL12 receptors control different cell functions.
Subcellular localization of CXCL12 receptors in tumor cell lines
The observed differential use of CXCR4 and CXCR7 by the different tumor cell lines prompted us to more closely define the subcellular localization of CXCL12 receptors in these cells (Fig. 5 ). For this analysis more than 100 cells of each tumor line were examined. Double-labeling of cells transfected with control siRNA with selective CXCR4 and CXCR7 antibodies demonstrated the predominant association of CXCR7 with the outer plasma membrane of C33A, DLD-1, MDA-231, and PC-3 cells and the partial association of CXCR7 within intracellular structures in DLD-1 and MDA-231 cells. In all these cells, CXCR4 was associated with both intracellular structures and to varying degrees with the outer cell membrane (Fig. 5A) . Moreover, CXCR7 and CXCR4 labelling widely overlapped in the plasma membrane of DLD-1 cells, but was predominantly restricted to different parts of the plasma membrane of MDA-231 cells (Fig. 5A) . In MDA-231 cells, CXCR4 staining was further associated with the nucleus as previously shown for other cancer cells [12] . A549 cells were unique since both CXCR7 and CXCR4 labelling was predominantly present within intracellular structures with an especially high co-localization of both receptors around the nucleus (Fig. 5A) . In case of MDA-231 cells, differences in the subcellular localization of CXCR4 and CXCR7 were confirmed by flow cytometry (Suppl. Fig. 2 ). This approach likewise demonstrated the predominant location of CXCR4 within intracellular structures and the association of CXCR7 with both the outer cell membrane and intracellular structures. Together, these findings unravel that the subcellular localization of CXCR4 and CXCR7 differs across different tumor cell lines.
Effects of cellular depletion of 5T4 on the use of CXCL12 receptors and their subcellular distribution
To assess putative influences of 5T4 on the use of CXCL12 receptors Fig. 2 . Contribution of CXCR4 and CXCR7 to CXCL12-dependent chemotaxis of tumor cell lines. Cultured tumor cells were maintained for 1 h in the presence or absence of either AMD3100 (10 µM), CCX771 (100 nM) or CCX704 (100 nM) and CXCL12-dependent chemotaxis was assayed in a modified Boyden chamber. The number of cells migrating in the absence of the chemokine was set to 1. Bars show the average migration index ( ± SD) as determined in 3-12 experiments. CXCL12 induced migration of all tumor cell lines. In C33A, MDA-231, and PC-3 cells, both AMD3100 and CCX771 attenuated CXCL12-dependent migratory responses, whereas migratory responses of A549 and DLD-1 cells were only sensitive to CCX771.
in the various cancer cell lines, we inhibited cellular 5T4 expression by RNA interference. Transfection with different pre-designed 5T4-siRNAs resulted in a 60-90% drop of 5T4 expression when compared to cells transfected with scrambled control siRNA ( Fig. 6 ; Suppl. Fig. 1 , Table 1 ). In most cell lines, the decline in 5T4 expression was not associated with obvious changes in CXCR4 and CXCR7 expression levels ( Fig. 6 ; Suppl. Fig. 1, Table 1 ). Only in DLD-1 cells, siRNA-dependent inhibition of 5T4 expression resulted in a pronounced, approximately 60% decline in CXCR7, but not in CXCR4 levels, as evidenced by both Western blotting and immunocytochemistry ( Fig. 6 ; 5B; Table 1 ). Transfection of C33-A, DLD-1, MDA-231, and PC-3 cells with 5T4 siRNAs further remained without obvious effects on the subcellular Fig. 3 . Effects of CXCL12 on tumor cell numbers. Tumor cell cultures were maintained for 48 h with varying concentrations of CXCL12 and subsequently analyzed for cell numbers by MTT assay. Cell numbers present in untreated controls were set to 1. Bars show relative cell numbers (mean ± SD) as determined in 3-7 experiments. CXCL12 at 100 ng/ml increased numbers of C33A, MDA-231, and PC-3 cells, but not those of A549 and DLD-1 cells. Stimulatory effects of CXCL12 on cell numbers either declined or became undetectable with increasing concentrations of CXCL12. Fig. 4 . Contribution of CXCR4 and CXCR7 to CXCL12-induced increases in tumor cell numbers. Cultured tumor cells were treated for 48 h with CXCL12 (100 ng/ml) in combination with AMD3100 (10 µM), CCX771 (100 nM) or CCX704 (100 nM) as indicated and subsequently analyzed for cell numbers by MTT assay. Cell numbers present in untreated controls were set to 1. Bars represent relative cell numbers (mean ± SD) as determined in 3-11 experiments. CXCL12-induced increases in C33A cell numbers were sensitive to both AMD3100 and CCX771 whereas the effects of CXCL12 on numbers of MDA-231 and PC-3 cells were only attenuated by AMD3100. distribution of CXCR4 and CXCR7 as observed in > 100 cells of each cell line (Fig. 5B, Suppl. Fig. 1, Table 2 ). By contrast, following transfection with 5T4 siRNA, A549 cells attained a flat morphology and additionally exhibited a relocation of CXCR4 and CXCR7 from perinuclear sites to the plasma membrane and cytoplasmatic structures (Fig. 5B) . Despite receptor re-localization, CXCR4 and CXCR7 staining still largely overlapped in 5T4-depleted A549 cells (Fig. 5B) .
To assess whether depletion of 5T4 would alter the use of CXCL12 receptors, we reanalyzed the effects of AMD3100 and CCX771 on CXCL12-induced chemotaxis in tumor cell lines previously transfected with 5T4 siRNA. We refrained from performing this analysis for CXCL12-induced cell proliferation since only a selection of the cell lines responded to the chemokine with increases in cell numbers (see Fig. 3 ). We found unchanged sensitivity of CXCL12-induced cell migration towards AMD3100 and/or CCX771 in A549, C33A, and MDA-231 cells with reduced 5T4 levels when compared to their wild-types (Figs. 2 and 7, Table 2 ). The slight decline of the migration index of C33A cells apparent in the presence of CCX704 was again likewise detectable in C33A cells treated with DMSO alone. Contrasting the findings with A549, C33A, and MDA-231 cells, 5T4-depleted PC-3 cells only showed sensitivity to AMD3100, but no longer to CCX771 (Figs. 2 and 7) . Finally, it is noteworthy that in A549, C33A, DLD-1, but not in MDA-231 and PC-3 cells, RNAi-mediated depletion of 5T4 per se attenuated the chemotactic response of the cells towards CXCL12 (Figs. 2 and 7) , an effect not detectable in cells transfected with control siRNA (Suppl. Fig. 3 ). This decline was most prominent in 5T4 siRNA-transfected DLD-1 cells and amounted to 70% (p < 0.001) when compared to cells transfected with control siRNA. It is of note that this decline related to a pronounced loss of CXCR7 in 5T4-depleted DLD-1 cells (Fig. 6) , the CXCL12 receptor subtype mediating chemotaxis in these cells (see Fig. 2 ). Depletion of 5T4 in A549 and C33A cells reduced chemotactic responses by 45% (p < 0.001) and 31% (p < 0.001), respectively. Collectively, these findings unravel that 5T4 is essential for the function of the CXCL12 system in some, but not in the majority of cancer cell lines. In addition, these observations unravel that 5T4 per se controls migration of selected tumor cells.
Since 5T4 was shown to attenuate CXCL12-dependent cell proliferation [5] , we further asked how RNAi-mediated depletion of 5T4 in tumor cells would interfere with their mitogenic responses to CXCL12. Cellular depletion of 5T4 per se resulted in a 160-200% increase in numbers of C33A and MDA-231, but not of PC-3 cells when compared to cultures transfected with control siRNA (Fig. 8) . Treatment of 5T4 siRNA-transfected C33A, MDA-231, and PC-3 cells with CXCL12 further increased cell numbers by roughly 150% (Fig. 8) . Together, these findings establish that 5T4 per se affects proliferation of distinct tumor cells. In addition, the findings provide evidence that 5T4 does not modulate mitogenic function of CXCL12 in all type of cells. 
Discussion
Our present analysis was spurred by previous findings in murine embryonic fibroblasts and small cell lung carcinomas showing that 5T4 not only controls CXCR7 expression, but also dictates the preference of CXCL12 to either CXCR4 or CXCR7, in terms that CXCL12 binds to CXCR4 in the presence of 5T4 and to CXCR7 in its absence [24] . We could not confirm a general correlation between 5T4 expression and CXCL12 receptor preference in our present analysis of five different human tumor cell lines, namely cervical, colorectal, breast, prostate, and non-small cell lung cancer cells. Although the tumor cell lines expressed 5T4 to detectable levels, CXCL12 promoted chemotactic cell responses either through CXCR7 (A549, DLD-1) or both CXCL12 receptors (C33A, MDA-231, PC-3) (see Table 2 ). Moreover, MDA-231 and PC-3 cells only required CXCR4 whereas C33A cells required both CXCR4 and CXCR7 to respond to CXCL12 with increases in cell numbers. The other tumor cell lines failed to respond to CXCL12 with increased cell proliferation. Importantly, in most tumor cell lines (A594, C33A, MDA-231) this individual receptor dependency remained unchanged following RNAi-mediated inhibition of 5T4 expression (see Table 2 ). In DLD-1 cells, depletion of 5T4 resulted in a selective loss of CXCR7 expression and the subsequent impairment of CXCL12-dependent chemotaxis. Finally, 5T4-depleted PC-3 cells only used CXCR4 for CXCL12-dependent chemotaxis.
The finding that depending on the tumor cell line, cellular responses Fig. 6 . Inhibition of cellular 5T4 expression by RNA interference. Cultured tumor cells were maintained for 1 h with serum-free medium and transfected with predesigned 5T4 siRNA or scrambled control siRNA. Twenty four hours following transfection, cells were lysed and subjected to Western blot analysis for 5T4, CXCR4 and CXCR7. GAPDH served as loading control. In all tumor cell lines, RNAi allowed for a pronounced inhibition of 5T4 expression. In DLD-1 cells, depletion of 5T4 was associated with a decline in CXCR7, but not CXCR4 expression, whereas in all other tumor cells reduced 5T4 levels had no effect on CXCR4 and CXCR7 expression. Tumor cells with depleted 5T4 levels were analyzed for expression of the indicated proteins by Western blotting. Labeled protein bands were quantified by densitometry and corrected for protein loading (GAPDH). Levels of respective proteins in non-transfected controls were set to 1. ns, not significant. of CXCL12 either involve CXCR7 and/or CXCR4 fits well with the emerging concept of the differential use of CXCL12 receptors by tumor cells [2] . This fact not only applies to different types of tumors, as evidenced by our present studies, but also to the same type of tumor from different patients or even to different cells within a given tumor.
Inter-individual differences in the organization of the CXCL12 system are currently best documented for glioma. Depending on the patient, CXCL12-dependent glioma growth and mobility either occurs through CXCR4 or CXCR7 [13] [14] [15] [16] . Another aspect of this heterogeneous organization is the control of different cell functions by different CXCL12 receptors [1, [8] [9] [10] . Notably, this level of heterogeneity was absent in most of cancer cell lines examined, but present in MDA-231 and PC-3 cells, as judged from the demonstration that antagonizing either CXCR4 or CXCR7 attenuated CXCL12-induced migration of these cells, whereas antagonizing CXCR4, but not CXCR7, prevented CXCL12-dependent proliferation of both cell lines. Previously, other groups reported that CXCL12 controls migration of A549 cells through CXCR4 and proliferation of PC-3 cells through CXCR7 [17, 18] . These discrepant findings could well reflect the fact that even the use of different culture conditions might influence the organization of the CXCL12 system in these cells. Interestingly, C33A, MDA-231, and PC-3 cells failed to respond to CXCL12 with cell migration and/or proliferation following inactivation of either CXCR4 or CXCR7. This is reminiscent of our previous findings with primary Schwann cells and microglia which likewise required both CXCL12 receptors for CXCL12-dependent cell responses [6, 7] . We currently consider these observations as an indication that in various cells, CXCR7 not simply modulates activity of CXCR4 as originally suggested [19] , but together with CXCR4 forms an active signaling unit. Whether this signaling unit depends on the formation of CXCR7/CXCR4 heterodimers or the cross talk of down-stream signaling pathways still awaits clarification.
It is well established that the subcellular localization of CXCL12 receptors differs between cells and is either associated with the plasma membrane, intracellular structures, or both [7, 13, [20] [21] [22] [23] . In all cancer cell lines except A549 cells, CXCR7 was preferentially associated with the outer cell membrane. Moreover, in all tumor lines CXCR4 localized to a varying degree to intracellular structures and the outer cell membrane. Again with exception of A549 cells, depletion of 5T4 did not result in an obvious re-localization of CXCL12 receptors in the tumor cell lines examined. Depletion of 5T4 in A549 cells induced a re-localization of CXCR7 and CXCR4 from perinuclear sites to intracellular structures and the outer cell membrane. These findings clearly contrast the previous observation made in other cell types that CXCR7 only localizes to the surface of cells lacking 5T4 [5] . Even more importantly, the subcellular distribution of CXCL12 receptors in a given tumor cell line did not allow any conclusion to the specific use of CXCR7 and/or CXCR4 in the respective cells. The absence of such a correlation could well reside within the fact that differences in the subcellular localization of CXCL12 receptors do per se not reflect trafficking of CXCR4 and/or CXCR7 between the outer cell membrane and intracellular compartments and, hence, their involvement in CXCL12 signaling of a given cell [24] [25] [26] .
We further failed to detect general modulatory influences of 5T4 on CXCL12-induced proliferation of the various tumor cell lines as previously reported for other types of cells [5] . However, in line with previous work [27] [28] [29] [30] , we found that in distinct tumor cell lines, 5T4 modulates CXCL12-induced chemotaxis as well as basal cell proliferation per se. Indeed, siRNA-mediated depletion of 5T4 attenuated CXCL12-dependent migration of C33A cells without affecting expression or subcellular localization of CXCL12 receptors. A different situation applied for DLD-1 and A549 cells. In DLD-1, depletion of 5T4 inhibited CXCR7 expression and, hence, CXCL12-dependent chemotaxis, whereas in A549 cells, reduced cell migration was accompanied by altered cell shape and re-distribution of CXCL12 receptors. Modulatory influences of 5T4 on basal cell proliferation became evident with C33A and MDA-231 cells, which increased in numbers following depletion of 5T4. Except for DLD-1 cells, the mechanisms by which 5T4 controls cell proliferation and/or migration are still unknown.
Conclusions
Based on the potent effects of CXCL12 on proliferation, survival, and migration of a large variety of tumor cells, the CXCL12 system is currently regarded as a prime target for therapeutic intervention in many types of tumors [1, [31] [32] [33] . This view spurred considerable interest over recent years to target CXCR4 and CXCR7 by selective peptides, small molecule inhibitors or single domain antibodies [32, [34] [35] [36] . Our work now emphasizes the fact that with this therapeutic approach, optimal benefits can only be achieved when the exact organization of the CXCL12 system in the respective patient/tumor is known. Unfortunately, our present work does not support a correlation between 5T4 expression and organization of the CXCL12 system in tumor cells, and, hence, dismisses 5T4 as a potential marker for the cellular organization of the CXCL12 system.
